• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

What Lies Ahead 2016

By DIA
Article

What Lies Ahead 2016

DIA’s exclusive annual survey catalogs, ranks, and describes trends to watch in biopharmaceutical, device, and related research, development, and regulation, from expert global and regional perspectives, in the year ahead.

Read the article here.

Recent Videos
Related Content
Zongertinib Demonstrates High Objective Response Rate in Previously Treated Advanced Non-Small Cell Lung Cancer

Zongertinib Demonstrates High Objective Response Rate in Previously Treated Advanced Non-Small Cell Lung Cancer

Don Tracy, Associate Editor
September 10th 2024
Article

Results from the Phase Ib Beamion LUNG-1 trial found that zongertinib achieved an objective response rate of 66.7% in previously treated patients with advanced non-small cell lung cancer with HER2 mutations.

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Miranda Schmalfuhs
September 6th 2024
Podcast

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

Pharma Pulse 9/10/24: How Satellite Sites Are Outpacing Decentralized Models, Large Numbers of People Clinically Eligible for GLP-1 Drugs & more

Pharma Pulse 9/10/24: How Satellite Sites Are Outpacing Decentralized Models, Large Numbers of People Clinically Eligible for GLP-1 Drugs & more

Miranda Schmalfuhs
September 10th 2024
Article

The latest news for pharma industry insiders.

Empty Shelves, Urgent Solutions

Empty Shelves, Urgent Solutions

Miranda Schmalfuhs
August 5th 2024
Podcast

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

Stock.adobe.com

Evernorth to Provide Stelara Biosimilar for 0$ Out-of-Pocket

Mike Hollan
September 10th 2024
Article

This is the second biosimilar that the company is offering to its customers at this price.

Thomas Shea

From Endemic to POC: The Journey Pharma Marketers Need to Tread

Thomas Shea
September 10th 2024
Article

The digital revolution has brought more efficient ways to reach and touch HCPs.